Biovica International
UPPSALA, SWEDEN / ACCESSWIRE / November 16, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model's results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.
Care for metastatic breast cancer patients is a large burden on healthcare systems due to cost of therapies, cost of monitoring tests, and management of side effects. The results from this study show that adding DiviTumTKa to care could give a net reduction in costs of up to three times the spend on the new test. The savings come from a decrease in the usage of other monitoring tools such as CT scans and bone scans, and from shortening the amount of time a patient receives expensive medical treatments that ultimately prove to be ineffective.
"Our analysis showed that inclusion of DiviTum®TKa could reduce use of a substantial proportion of traditional monitoring. If use of DiviTum®TKa can also predict lack of benefit from costly CDK4/6i therapy and clinicians then act on that information in a timely fashion, our model suggests that this will result in substantial cost savings to patients and health plans," said Scott D. Ramsey from the Fred Hutchison Cancer Research Center.
"This analysis reinforces our belief that DiviTum®TKa will improve the lives of patients and reduce costs in healthcare. From discussions with patients, we also know that they prefer a regular blood test as a better option than current monitoring practices." said Anders Rylander, CEO of Biovica.
The study publication is included in the November 2021 issue of the Journal of Medical Economics https://doi.org/10.1080/13696998.2021.2003674
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Biovica's DiviTum®TKa results published in Journal of Medical Economics
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673068/Biovicas-DiviTumRTKa-Results-Published-in-Journal-of-Medical-Economics
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Announces Launch of MCP Server to Let AI Execute Analytics End-to-End21.1.2026 10:00:00 CET | Press release
Combining MCP, analytics-as-code, and LLMs to automate analytics execution at software speed SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / GoodData, a leader in AI analytics and decision intelligence, today announced the public launch of its MCP Server. As organisations adopt AI in analytics, most tools remain limited to query generation, leaving teams to manually manage metrics, dashboards and business logic. MCP Server moves AI beyond analysis, enabling governed, end-to-end analytics execution and delivering 10-50x faster time to value. The MCP Server is designed for AI developers, and BI and data teams who want to build and manage analytics faster with AI. It allows AI to build and operate analytics in the same way a skilled human team would, but faster and without operational bottlenecks. Using the Model Context Protocol (MCP), AI agents and large language models (LLMs) can connect directly to GoodData and execute analytics across the full lifecycle. They can wor
Kontent.ai Launches AI-Powered SEO and GEO Workflows to Cut Optimization Time by Up to 80% and Optimize Content for Search and Answer Visibility21.1.2026 08:00:00 CET | Press release
Kontent.ai today announced the launch of new agentic SEO and Generative Engine Optimization (GEO) workflows following early results that show organizations reducing the time required to audit and optimize content performance by up to 80 percent while improving organic and answer engine reach without additional media spend. BRNO, CZ / ACCESS Newswire / January 21, 2026 / As content inventories grow into hundreds of thousands of items, search engine optimization (SEO) has become a significant operational cost. Manual audits, spreadsheet-driven updates, and disconnected tooling make it difficult for teams to keep content accurate, structured, and discoverable across both traditional search engines and AI-driven discovery platforms. Kontent.ai's new agentic workflows are designed to change that cost and effort curve. Embedded directly within the CMS, autonomous agents continuously analyze content for missing or inconsistent metadata, unclear structure, outdated terminology, and weak intern
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
Innodata Awarded Prime Contract Position on U.S. Missile Defense Agency's IDIQ SHIELD Program20.1.2026 14:30:00 CET | Press release
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. The SHIELD program is designed to drive rapid innovation and deliver next-generation capabilities that strengthen the nation's multi-layered homeland defense architecture. As part of the broader Golden Dome strategy, this selection positions Innodata to compete for future task orders across research, development, engineering, prototyping, and operations of critical Missile Defense Agency systems that support U.S. national security objectives. The award was made as part of a list of companies eligible to compete under the program publicly announced by the U.S. Government on 15-Jan-26. "We are proud to support our nation's mission to defend the homeland," said Vinay Malkani, SVP Federal of Innodata. "This co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom